35034660|t|Short structural variants as informative genetic markers for ALS disease risk and progression.
35034660|a|There is considerable variability in disease progression for patients with amyotrophic lateral sclerosis (ALS) including the age of disease onset, site of disease onset, and survival time. There is growing evidence that short structural variations (SSVs) residing in frequently overlooked genomic regions can contribute to complex disease mechanisms and can explain, in part, the phenotypic variability in ALS patients. Here, we discuss SSVs recently characterized by our laboratory and how these discoveries integrate into the current literature on ALS, particularly in the context of application to future clinical trials. These markers may help to identify and differentiate patients for clinical trials that have a similar ALS disease mechanism(s), thereby reducing the impact of participant heterogeneity. As evidence accumulates for the genetic markers discovered in SQSTM1, SCAF4, and STMN2, we hope to improve the outcomes of future ALS clinical trials.
35034660	61	72	ALS disease	Disease	MESH:D000690
35034660	156	164	patients	Species	9606
35034660	170	199	amyotrophic lateral sclerosis	Disease	MESH:D000690
35034660	201	204	ALS	Disease	MESH:D000690
35034660	501	504	ALS	Disease	MESH:D000690
35034660	505	513	patients	Species	9606
35034660	645	648	ALS	Disease	MESH:D000690
35034660	773	781	patients	Species	9606
35034660	822	833	ALS disease	Disease	MESH:D000690
35034660	879	890	participant	Species	9606
35034660	968	974	SQSTM1	Gene	8878
35034660	976	981	SCAF4	Gene	57466
35034660	987	992	STMN2	Gene	11075
35034660	1036	1039	ALS	Disease	MESH:D000690
35034660	Association	MESH:D000690	11075
35034660	Association	MESH:D000690	57466
35034660	Association	MESH:D000690	8878

